Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-065173
Filing Date
2025-05-07
Accepted
2025-05-07 10:00:20
Documents
71
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mcrb-20250331.htm   iXBRL 10-Q 2258526
2 EX-10.2 mcrb-ex10_2.htm EX-10.2 43109
3 EX-31.1 mcrb-ex31_1.htm EX-31.1 14941
4 EX-31.2 mcrb-ex31_2.htm EX-31.2 14772
5 EX-32.1 mcrb-ex32_1.htm EX-32.1 9113
6 EX-32.2 mcrb-ex32_2.htm EX-32.2 9164
  Complete submission text file 0000950170-25-065173.txt   8156661

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20250331.xsd EX-101.SCH 1061043
74 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20250331_htm.xml XML 1263613
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 25919698
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)